MAKE APPOINTMENT

Manufacturing Site Problems, Not Trial Results, Push Back FDA Decision on Novo’s Once-Monthly Hemophilia A Drug Denecimig

by | Oct 5, 2026 | Uncategorized | 0 comments

FDA’s review of Novo’s hemophilia A drug denecimig is delayed by manufacturing site issues, not trial data. Launch is now targeted for 2027.

Submit a Comment

Your email address will not be published. Required fields are marked *